Skip to content

Comparison of Misoprostol and PGE2 Gel for Induction of Labour in Women With Premature Rupture of Membranes at Term

Comparison of Misorostol & PGE2 Gel for Immediate Induction of Labour for Premature Ropture of Membranes at Term

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00355966
Enrollment
212
Registered
2006-07-25
Start date
2006-08-31
Completion date
2008-09-30
Last updated
2010-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Rupture of Membranes at Term

Keywords

Premature rupture of membranes, Induction of labour with Misoprostol, Induction of labour with PGE2 gel

Brief summary

Induction of labour with vaginal misoprostol, in women with premature rupture of membranes at term, results in significant shortening of induction to delivery time in comparison to vaginal PGE2 gel induction.

Interventions

DRUGMisoprostol

In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .

In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.

Sponsors

Nilratan Sircar Medical College
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Premature rupture of membranes at 37 or more weeks * Single live fetus in cephalic presentation

Exclusion criteria

* Women in labour * Women with contraindication of induction of labour * Women with previous caesarean section or uterine surgery

Design outcomes

Primary

MeasureTime frame
Admission to delivery time48 hours

Secondary

MeasureTime frame
Caesarean Section rate48 hours
Neonatal morbidityTill discharge
Maternal morbidityTill discharge

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026